Pharmaceutical

Sanofi Accelerates Transformation Sanofi Sanofi accelerates its transformation into a biopharmaceutical company with strategic investments and the sale of its consumer health division. The article explores its latest moves in oncology, fibrosis, and RNA therapies, while navigating industry challenges.
Flare Therapeutics partners with Roche in a strategic collaboration Flare Therapeutics Roche Flare Therapeutics partners with Roche in a strategic collaboration to discover small molecule cancer drugs targeting untapped transcription factors, with a focus on oncology and rare genetic diseases.
AstraZeneca Announces Major Developments AstraZeneca AstraZeneca announces a $3.5 billion investment in the U.S., upgrades its 2024 performance forecast, and submits a BLA for Trop2 ADC to treat EGFR-mutant NSCLC. Key developments aimed at growth and innovation.
Semaglutide Treatment for Peripheral Artery Disease Phase III Study Successful Semaglutide Novo Nordisk Novo Nordisk announces the successful completion of the Phase IIIb STRIDE study for semaglutide in treating Peripheral Artery Disease (PAD) and submits IcoSema for EU approval. Additionally, Mim8 shows promising results for hemophilia A treatment.
100 Hospitalized, 10 Dead! Novo Nordisk Issues Warning Novo Nordisk FDA Novo Nordisk warns after 100 hospitalizations and 10 deaths linked to generic versions of its weight loss and diabetes drugs, Wegovy and Ozempic. The company urges the FDA to ban unsafe generics due to complex formulations and safety concerns.
FDA Approval of Emrosi for Rosacea Treatment FDA Journey Medical FDA approves Journey Medical's Emrosi™, a 40 mg extended-release minocycline capsule, for treating adult rosacea. Supported by successful Phase III trials, Emrosi is set to launch in the U.S. by mid-2025 as a new oral standard for rosacea treatment.
Improvement in Liver Fibrosis with Semaglutide Semaglutide Novo Nordisk Novo Nordisk announces promising Phase III results from the ESSENCE study of semaglutide, showing significant improvement in liver fibrosis for patients with metabolic dysfunction-associated fatty liver disease (MAFLD). With plans for regulatory approval applications in 2025.
GLP-1RA Biweekly Formulation Outperforms Semaglutide! GanLee Insulin Semaglutide Ganlee Pharmaceuticals’ Phase II trials show promising results for innovative diabetes treatments. Their biweekly GLP-1RA, GZR18, demonstrates superior HbA1c and weight reduction compared to Semaglutide, while GZR4 and GZR101 also show favorable outcomes versus Insulin Degludec and Degludec/Aspart.
Next-Generation Weight Loss Drug Star on the Rise, BD Expected to Reach Full Capacity Weight loss drugs Laekna Novo Nordisk Eli Lilly The weight loss drug market is heating up, with Eli Lilly, Novo Nordisk, and Chinese pharma companies competing in research and development. ActRII-targeted drugs, combining fat loss and muscle gain. Laekna's LAE102 has shown promising results, driving a 40% surge in its stock.
Hengrui Medicine, Head-to-Head Challenge with Semaglutide Semaglutide Hengrui Pharmaceuticals Weight loss drugs Hengrui Pharmaceuticals is challenging semaglutide with its GLP-1R/GIPR dual agonist HRS9531 in a head-to-head clinical trial for type 2 diabetes. Early data from EASD 2024 shows significant HbA1c reduction, weight loss, and good tolerability, paving the way for further development.